A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus
Phase of Trial: Phase I/II
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Gacyclidine (Primary)
- Indications Tinnitus
- Focus Adverse reactions
- Sponsors Otonomy
- 05 Nov 2019 According to an Otonomy media release, results from this trial are expected in second quarter of 2020.
- 15 Apr 2019 Status changed from planning to recruiting.
- 04 Mar 2019 According to an Otonomy media release, the company expects to complete this trial in first half of 2020.